Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.
about
Potential impact of co-infections and co-morbidities prevalent in Africa on influenza severity and frequency: a systematic reviewSeasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics - a systematic literature reviewInsights on common vaccinations in HIV-infection: efficacy and safetyInfluenza vaccination in HIV-positive subjects: latest evidence and future perspectiveOptimal design of intervention studies to prevent influenza in healthy cohortsMortality Associated With Seasonal and Pandemic Influenza Among Pregnant and Nonpregnant Women of Childbearing Age in a High-HIV-Prevalence Setting-South Africa, 1999-2009.Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant WomenInfluenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement.Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010-2011.Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their InfantsRandomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand.Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America.Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infectionSafety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccineSevere influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009-2011.South African guideline for the management of community-acquired pneumonia in adults.Vaccination of HIV-infected pregnant women: implications for protection of their young infants.Influenza A Virus Infection and Nucleotide Sequencing in HIV-Infected Children: A Case Report and Review of Literature.Immunization of HIV-infected adult patients - French recommendations.Impact of Human Immunodeficiency Virus on the Burden and Severity of Influenza Illness in Malawian Adults: A Prospective Cohort and Parallel Case-Control Study.Hintergrundpapier der STIKO: Evaluation der bestehenden Influenzaimpfempfehlung für Indikationsgruppen und für Senioren (Standardimpfung ab 60 Jahren).A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.
P2860
Q23909568-FC04E4FA-4A07-44FA-BA2F-CCADEA15268CQ26769664-9AE143D1-C6DD-4235-B14C-B82612B1EA18Q26770665-59844EF3-5322-4B67-B7EB-93A43653D430Q27007483-176CEA21-3634-48A6-95F6-7503AD60726CQ28730583-A84E48D4-9723-40DF-A6C5-59C03216E242Q30375504-0318E8EE-7FCA-46DE-8A97-1EEBD7E4A8D7Q30378589-4972F702-8422-41A7-B58D-2E0D69411319Q30397977-15AEC153-1D7D-4C05-A784-00093A3434B3Q30400385-7A5F6469-AD55-402B-B2E1-837656E82D1DQ30404293-8075510E-6FFF-4124-9F24-1E3E0B323F13Q34390072-735C1046-20FE-4E14-BD60-85DBA47D9600Q35047483-78C1A72A-1C87-496C-8AD4-C10F41BF8F2BQ36256314-2BFA9C68-DD63-4F2C-A4D3-D4B788195C67Q36306940-E6EC4A41-D4D5-4289-81D8-9F2C4912200FQ36447589-72CAE320-3531-46B5-93E7-F195329CAD71Q36748191-B72459E0-0DC4-4B79-9FB8-AF7DD378BC25Q36854000-77EB5F52-49A1-4746-B347-5567548BD6BAQ36984193-703B3108-80E6-4D97-982A-F8809E4DAF25Q37309289-72ABDF93-CCFF-4769-AEA6-8CE1D192141AQ37335166-AA12BC97-DC25-4462-8D36-6ED2B94F7895Q39455917-EC5CDDC4-88BF-41DF-B42E-EDC7E550FC05Q40051928-CE8BFD34-61CF-4EC0-A3C0-8417B3126685Q40081758-209D2B9B-BFA5-4B0F-8DB4-8DFC67DEA194Q40615516-CF14787B-E47A-46E4-AFEF-153A946176D9Q43365954-83AFFF92-50EB-41FE-AD98-8575C1A49E6BQ52845428-675C9DE4-9255-4481-B0D3-B86A9A5E3B81Q54626497-FEECCA64-C049-4D23-A91A-FA0F712ADBB6
P2860
Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Trivalent inactivated influenz ...... y, immunogenicity, and safety.
@en
Trivalent inactivated influenz ...... y, immunogenicity, and safety.
@nl
type
label
Trivalent inactivated influenz ...... y, immunogenicity, and safety.
@en
Trivalent inactivated influenz ...... y, immunogenicity, and safety.
@nl
prefLabel
Trivalent inactivated influenz ...... y, immunogenicity, and safety.
@en
Trivalent inactivated influenz ...... y, immunogenicity, and safety.
@nl
P2093
P2860
P50
P356
P1476
Trivalent inactivated influenz ...... y, immunogenicity, and safety.
@en
P2093
Anthonet Koen
Dhamari Naidoo
Martine Valette
Terry G Besselaar
P2860
P304
P356
10.1093/CID/CIQ004
P407
P577
2011-01-01T00:00:00Z